Indole-based compounds have been explored as antimalarial agents because they can disrupt the Plasmodium cell cycle. In a recent study, researchers from the University of São Paulo and the Federal University of São Carlos reported the evaluation of scaffolds selected from three classes of indole hybrids against Plasmodium falciparum.

Ovarian clear-cell carcinoma is a cancer characterized by inherent resistance to platinum-based therapies and lacks an effective targeted therapeutic approach. On the other hand, chaperone-mediated autophagy is a lysosomal degradation mechanism to stabilize cellular homeostasis during stressful scenarios, but its role in modulating platinum response in ovarian cancer is not well understood.

One in six common bacterial infections diagnosed worldwide in 2023 were resistant to treatment with antibiotics, according to the latest surveillance data gathered by the World Health Organization (WHO). Drug-resistant gram-negative bacteria that cause bloodstream infections that can lead to sepsis, organ failure and death are an increasing threat globally.

Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations.

Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a system to repel an attack, it can also be dismantled. Scientists at the University of Southampton have described the components of Kiwa, a protein complex that blocks the entry of phage DNA, which are viruses that infect bacteria. They have also uncovered how Kiwa interacts with other bacterial defense strategies.

The boronic acid transition state inhibitors S-02030 and MB-076 were strategically designed to be active against cephalosporinases and carbapenemases, especially KPC (Klebsiella pneumoniae carbapenemase).

The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.

Understanding the mechanisms of resistance to cancer treatments is necessary to find effective therapies at different stages of the disease. Scientists at UT Southwestern Medical Center studied the most frequent mutation in pancreatic ductal adenocarcinoma (PDAC), identified an escape route to a therapy in clinical trials, blocked it with another experimental compound and reduced tumors in mice.